MedTrace Logo

Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.

NCT04191863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2020-05-07

No results posted yet for this study

Summary

Our study, retrospectively evaluate the characteristics of and the risk factors for the occurrence of nocturnal enuresis in epileptic children kept on valproate monotherapy.

Epileptic children with the age ranged 5 up to 15 years who were started and kept up on valproate monotherapy. In this study, a child determined to have nocturnal enuresis based on the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, fourth edition: "an involuntary voiding of urine during sleep, with a severity of at least twice a week, in children aged 5 years or older, in the absence of congenital or acquired defects of the nervous system."

Conditions

Interventions

OTHER

Clinical, EEG and laboratory assessment at presentation

* The patients' history, clinical, demographic, and laboratory data were acquired. * The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate. * Urinary tract ultrasonography (with full and void bladder). * CT brain and EEG.

DRUG

Valproate

valproate monotherapy

Sponsors & Collaborators

  • Mansoura University Hospital

    lead OTHER

Principal Investigators

  • Esmael M Ahmed, MD · Assistant Prof of Neurology

Eligibility

Min Age
5 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-06-01
Completion
2019-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04191863 on ClinicalTrials.gov